LibertyHealthSciences | LibertyHealthSciences.com Investor Report March 2019 LibertyHealthSciences | LibertyHealthSciences.com Investor Report March 2019
Investor Presentation
April 2019
CSE:LHS | OTCQX:LHSIF
Investor Presentation CSE:LHS | OTCQX:LHSIF April 2019 - - PowerPoint PPT Presentation
LibertyHealthSciences | LibertyHealthSciences.com LibertyHealthSciences | LibertyHealthSciences.com Investor Report March 2019 Investor Report March 2019 Investor Presentation CSE:LHS | OTCQX:LHSIF April 2019 LibertyHealthSciences |
LibertyHealthSciences | LibertyHealthSciences.com Investor Report March 2019 LibertyHealthSciences | LibertyHealthSciences.com Investor Report March 2019
April 2019
CSE:LHS | OTCQX:LHSIF
LibertyHealthSciences | LibertyHealthSciences.com Investor Report March 2019
Disclaimer
This documentation is a presentation (the “Presentation”) of general background information about Liberty Health Sciences Inc.’s (“Liberty Health Sciences”) activities current as of April 2019. It is information in a summary form and does not purport to be complete. It is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. These should be considered, with or without professional advice, when deciding if an investment is appropriate. This Presentation does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe for securities nor shall it or any part of it form the basis of
purchase or subscription must not be made on the basis of the information contained in this Presentation but are referred to the entire body of publicly disclosed information regarding Liberty Health Sciences. The information contained in this Presentation is derived solely from management of Liberty Health Sciences and otherwise publicly available information concerning Liberty Health Sciences and does not purport to be all-inclusive or to contain all the information that an investor may desire to have in evaluating whether or not to make an investment in Liberty Health Sciences. The information has not been independently verified and is subject to material updating, revision and further amendment, and is qualified entirely by reference to Liberty Health Science’s publicly disclosed information. No representation or warranty, express or implied, is made or given by or on behalf of Liberty Health Sciences or any of its affiliates, directors, officers or employees as to the accuracy, completeness or fairness of the information or opinions contained in this Presentation and no responsibility or liability is accepted by any person for such information or opinions. Liberty Health Sciences does not undertake or agree to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation that may become apparent. No person has been authorized to give any information or make any representations other than those contained in this Presentation and, if given and/or made, such information or representations must not be relied upon as having been so authorized. The information and opinions contained in this Presentation are provided as at the date of this Presentation. The contents of this Presentation are not to be construed as legal, financial or tax advice. Each prospective investor should contact his, her or its own legal adviser, independent financial adviser or tax adviser for legal, financial or tax advice. Certain statements in this Presentation may constitute forward-looking information, including future-oriented financial information and financial outlooks, within the meaning of applicable securities laws. Forward-looking information may relate to Liberty Health Sciences’ future outlook and anticipated events or results and may include statements regarding Liberty Health Sciences’ financial results, future financial position, expected growth of cash flows, business strategy, budgets, projected costs, projected capital expenditures, taxes, plans, objectives, potential synergies, industry trends and growth opportunities. Often but not always, forward-looking information can be identified by the use of words such as “anticipate”, “believe”, “expect”, “project”, “estimate”, “likely”, “intend”, “should”, “could”, “may”, “might”, “target”, “plan” and other similar expressions or variations (including negative variations) of such words and phrases. Forward-looking information contained in this Presentation is based on certain assumptions regarding expected growth, results of operations, performance, industry trends and growth opportunities. Although Liberty Health Sciences has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Forward-looking statements contained herein are made as of the date hereof and Liberty Health Sciences and its directors, officers and employees disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or results or
management’s general expectations concerning the medical marijuana industry are based on estimates prepared by management using data from publicly available industry sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which management believes to be reasonable. However, this data is inherently imprecise, although generally indicative of relative market positions, market shares and performance
published in whole or in part by any other person. Neither this Presentation nor any copy of it may be taken or transmitted into or distributed in any other jurisdiction which prohibits the same except in compliance with applicable laws. Any failure to comply with this restriction may constitute a violation of applicable securities law. Recipients are required to inform themselves of, and comply with, all such restrictions or prohibitions and Liberty Health Science does not accept liability to any person in relation thereto.
LibertyHealthSciences | LibertyHealthSciences.com Investor Report March 2019
Key Investment Highlights
standards
license to open dispensary and processing operations; Massachusetts - medical license with upside in adult-rec
to bring world-class cultivation, extraction, formulation and branding to Florida.
LibertyHealthSciences | LibertyHealthSciences.com Investor Report March 2019
Liberty currently holds a vertical license in Florida, where it operates cultivation, processing, dispensing and delivery businesses. Liberty also holds provisional dispensary and processing licenses in Ohio, and expects to open its dispensary and processing operations in Spring 2019. Liberty also holds a vertical license in Massachusetts, where it is evaluating its real estate opportunities.
LHS Footprint
LibertyHealthSciences | LibertyHealthSciences.com Investor Report March 2019
LibertyHealthSciences | LibertyHealthSciences.com Investor Report March 2019
Florida Market
Diverse Qualifying Base
Population: 21,300,000 Market: Est. US$0.8bn to US$1.1 billion by 2020 Scope: Medical use only Qualifying Patients: 6 million estimated (30%) Registered Patients: 260,000+ Ordering Physicians: 2,100+
Dispensaries: 114 dispensaries (currently statewide) Legal Product Scope: Flower/Bud, Cannabis Concentrates, Capsules, Transdermals and Ointments Canada has approximately 245K people per license in comparison to Florida which has 1.5M people per license
LibertyHealthSciences | LibertyHealthSciences.com Investor Report March 2019
Liberty Operations in Florida
Square Footage: 230,000 sq. ft. of cultivation space
People Employed: 200+ Current # of Patients Served: 15,000+ Average Basket Size: $120 Current Growing Capacity: 14,200 kg per year Production Locations: Alachua, Florida and Gainesville, Florida Total Acreage Owned: >400 acres # of Dispensaries Opened: 13 with a further 18 planned by the end of September 2019; integration with existing delivery hubs planned through 2019
LibertyHealthSciences | LibertyHealthSciences.com Investor Report March 2019
Liberty 360
Liberty 360 enables LHS to increase production to meet growing market demand a year earlier than the
completed and approved by the Department of Health. The existing Chestnut Hill facility will continue to be used for production purposes in order to meet the growing market demand for product. Increased capacity and utilization of efficient greenhouse cultivation will result in Liberty being the lowest cost producer in the state.
LibertyHealthSciences | LibertyHealthSciences.com Investor Report March 2019
550kg annually Facility: 14,200 sq. ft.
Production Capacity Growth
3,000kg annually Facility: 45,000 sq. ft.
1,200kg annually Facility: 25,000 sq. ft.
14,200kg annually Facility: 319,000 sq. ft.
LibertyHealthSciences | LibertyHealthSciences.com Investor Report March 2019
Whole Flower Pre-rolled Marijuana
Processing Capabilities
LibertyHealthSciences | LibertyHealthSciences.com Investor Report March 2019
Brands Hardware
Brands and Partnerships
CBD Terpenes
LibertyHealthSciences | LibertyHealthSciences.com Investor Report March 2019
Florida Strategy
Liberty’s growth in Florida will come through our expansion in three critical areas:
Coming Soon:
Boca Raton Boynton Beach Cape Coral Coral Springs Daytona
Hollywood Jacksonville Beach Mary Esther Orlando Panama City Pensacola Sarasota
Tallahassee West Palm Beach
Current Dispensaries:
LibertyHealthSciences | LibertyHealthSciences.com Investor Report March 2019
Key Investment Highlights and Market Potential
FLORIDA Population: 21,300,000 Qualifying Patients: 6,066,000 (30%)
OHIO Population: 11,600,000 Qualifying Patients: 2,804,359 (24%)
MASSACHUSETTS Population: 6,860,000 Qualifying Patients: 557,231 (8%)
TOTAL MARKET SIZE: Population: 39.8 million Qualifying Patients: 9.4 million